Special Issue "CRISPR, Cancer, and p53"
Deadline for manuscript submissions: closed (31 December 2019).
Interests: gene therapy, drug delivery systems, targeted systemic delivery of nucleic acids to cancer, phage display technology, metastases
Mutations of the tumor suppressor p53 gene are the most frequent abnormality identified in human tumors. Restoration of the natural function of p53 has been used as a therapeutic strategy against cancer. Gene delivery to transfer a wild-type copy of the p53 sequence to cancer has been tested as safe and efficient in clinical trials. However, the mutant p53 version still persists within malignant cells, which could interfere with its therapeutic efficacy. Additionally, mutations are distributed throughout the whole p53 gene. Therefore, replacing the entire p53 locus should increase therapeutic efficacy of targeting p53. In this context, a CRISPR-based gene editing system presents a viable approach for the stable recovery of p53 wild-type function via the full replacement of the mutant locus within the tumor genome with a normal p53 copy. Yet, the success of this strategy will depend on the ideal vector that can deliver a CRISPR functional cassette to tumors in an efficient and selective manner. The present Special Issue aims to introduce the potential applications of CRISPR in correcting the p53 function in cancer and the role of nucleic acid delivery technologies that could present a breakthrough in CRISPR-mediated targeted replacement of an abnormal p53 gene in cancer.
Dr. Amin Hajitou
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Tumor suppressor genes
- CRISPR-based genome editing
- Gene therapy
- Nucleic acid delivery technologies
- Targeted therapy